ARS Pharmaceuticals, Inc. SPRY Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Revenue Under Collaboration Agreements | $2.49M+1,085% | $6.86M-91.4% | $55K-96.3% | $2.59M+419% | $210K— | |
| Revenue Under Supply Agreements | $2.74M— | $901K+147% | $1.15M— | $323K— | $0— | |
| Revenue by Geography | ||||||
| DK | $2.78M+1,222% | —— | —— | —— | $210K— | |
| Non Us | $2.45M— | —— | —— | —— | $0-100% | |
| US | $17.45M+125% | —— | —— | —— | $7.76M+328% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ARS Pharmaceuticals, Inc. break its business down?
- ARS Pharmaceuticals, Inc. (SPRY) reports revenue by product across 2 parts — Revenue Under Collaboration Agreements and Revenue Under Supply Agreements. Each is extracted from the segment footnotes and tracked over time.
- Where does ARS Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ARS Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
